Scientists create controlled flu infection model to speed up vaccine testing
NCT ID NCT07305207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial aims to safely and reliably cause mild flu symptoms in healthy adults using a lab-made H3N2 influenza virus. By carefully monitoring 32 volunteers, researchers hope to establish a controlled human infection model (CHIM) that can be used in future studies to test new flu vaccines and treatments. Participants will receive either the virus or a placebo via nasal spray and be closely observed for a week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Live recombinant influenza virus (RG-A/Texas/71/2017 H3N2)
What this could lead to
If successful, this model could help test future flu vaccines and treatments more efficiently.
What could go wrong
This is a very early phase 1 study with only 32 participants. It is designed to cause mild flu symptoms, so some discomfort is expected. The model may not perfectly mimic natural infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••